NewcelX Ltd.

What they do

NewcelX develops and manufactures proprietary allogeneic cell products derived from human embryonic stem cells, designed to be available off-the-shelf for therapeutic use. The company operates as a Swiss corporation with a wholly owned U.S. subsidiary, NLS Pharmaceutics Inc. On October 30, 2025, it completed a merger with Israeli company Kadimastem Ltd., after which it changed its name from NLS Pharmaceutics Ltd. to NewcelX Ltd.

Revenue drivers

• Pre-commercial cell therapy pipeline — The company is clinical-stage and does not report product revenue; its value is tied to advancing its allogeneic hESC-derived cell product candidates through development.
• Kadimastem merger — The October 30, 2025 merger with Kadimastem combined the two companies' cell therapy assets and capabilities, with Kadimastem shareholders receiving 0.706 NewcelX common shares per Kadimastem ordinary share.
• Manufacturing capability — NewcelX describes developing and manufacturing proprietary cell products, indicating internal process development and production as a core activity rather than a marketed product line.

Recent performance

NewcelX reported a net loss of $8.3 million for 2025, compared with a net loss of $7.2 million in 2024 and $3.3 million in 2023. Operating cash flow was negative $2.8 million in 2025, versus negative $1.1 million in 2024. At December 31, 2025, total assets were $11.4 million, total liabilities $4.2 million, and shareholder equity $7.3 million, with cash and equivalents of $2.2 million. The company remains pre-revenue and funds operations from its balance sheet.

Strategy

The company's stated focus is on developing and manufacturing off-the-shelf allogeneic cell products based on its hESC expansion and differentiation platform. The October 2025 merger with Kadimastem was the defining recent strategic step, combining the two businesses under the NewcelX name and Nasdaq ticker NCEL. Management's priorities, as reflected in the filing, center on advancing this cell therapy platform and integrating the merged operations.

Risks

• Pre-revenue clinical-stage risk — NewcelX has no product revenue and reported a $8.3 million net loss in 2025, so its prospects depend entirely on successfully developing its cell therapy candidates.
• Limited cash runway — With $2.2 million in cash and equivalents at December 31, 2025, against operating cash burn of $2.8 million in 2025, the company will likely need additional financing.
• Merger integration risk — The October 30, 2025 merger with Kadimastem combined two organizations and shareholder bases, and integration may not achieve the intended benefits.
• Dilution risk — Shares outstanding rose from 4,797,505 at December 31, 2025 to 5,345,184 at April 29, 2026, indicating recent equity issuance that dilutes existing holders.

Outlook

The filing describes NewcelX as a clinical-stage company focused on advancing its allogeneic hESC-derived cell products following the Kadimastem merger. No product revenue is reported, and the company's near-term path depends on development progress and financing. With cash of $2.2 million at year-end 2025 and continued operating losses, funding needs are likely to remain a central issue.